Current characteristics of a population of psoriatic arthritis and gender disparities
Background and aim: Psoriatic arthritis (PsA) is a polymorphic disease associated with numerous comorbidities. The objective of this study was to describe the main clinico-biological and imaging characteristics of a population of PsA and to extract any disparities between men and women.
Methods: A total of 132 patients in the rheumatology department of Amiens University Hospital with a confirmed diagnosis of PsA according to the CASPAR criteria were included over a period of 4 months. All data were collected retrospectively in this observational and single-center study.
Results: The sex ratio was 1 and the average age at inclusion was 54.9 years. Peripheral PsA was the predominant clinical form. Axial PsA represented 12.1% of cases. Enthesitis was noted in 52.3% of cases while dactylitis was identified in 29.5% of cases. Moreover, 12.1% had a joint symptomatology preceding the appearance of cutaneous signs. HLA-B*27 positivity was found in 33.3% of cases. Chronic hyperuricemia accounted for 10% of our population. Sacroiliitis was observed in 41% of cases. The disparities between men and women are multiple and consistent with the literature: polyarticular form, enthesitis, obesity, more intensive prescription of s-DMARDs, and b-DMARDs are more associated with the female population. Oligoarticular form, psoriatic nail dystrophy, radiological axial involvement and chronic hyperuricemia are more encountered in the male population.
Conclusions: Our study found a very heterogeneous disease, with marked differences between men and women. Peripheral PsA remains predominant but the search for associated axial involvement, which is probably underestimated, seems essential.
Relevance for Patients: This work studied the main characteristics of patients with PsA followed in real life, in a regional university reference center. We have highlighted a very heterogeneous disease as well as some gender disparities, not well described in the literature, which should be taken into account in order to optimize therapeutic management.
[1] Alamanos Y, Voulgari PV, Drosos AA. Incidence and Prevalence of Psoriatic Arthritis: A Systematic Review. J Rheumatol 2008;35:1354-8.
[2] Liu JT, Yeh HM, Liu SY, Chen KT. Psoriatic Arthritis: Epidemiology, Diagnosis, and Treatment. World J Orthop 2014;5:537-43.
[3] Ogdie A, Weiss P. The Epidemiology of Psoriatic Arthritis. Rheum Dis Clin North Am 2015;41:545-68.
[4] Chandran V, Raychaudhuri SP. Geoepidemiology and Environmental Factors of Psoriasis and Psoriatic Arthritis. J Autoimmun 2010;34:J314-21.
[5] Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR Recommendations for the Management of Psoriatic Arthritis with Pharmacological Therapies: 2019 Update. Ann Rheum Dis 2020;79:700-12.
[6] Coates LC, Corp N, van der Windt DA, O’Sullivan D, Soriano ER, Kavanaugh A. GRAPPA Treatment Recommendations: 2021 Update. J Rheumatol 2022;49:52-4.
[7] Gladman DD, Chandran V. Observational Cohort Studies: Lessons Learnt from the University of Toronto Psoriatic Arthritis Program. Rheumatology (Oxford) 2011;50:25-31.
[8] Aouad K, Moysidou G, Rakotozafiarison A, Fautrel B, Gossec L. Outcome Measures Used in Psoriatic Arthritis Registries and Cohorts: A Systematic Literature Review of 27 Registries or 16,183 Patients. Semin Arthritis Rheum 2021;51:888-94.
[9] Coates LC, van der Horst-Bruinsma I, Lubrano E, Beaver S, Drane E, Ufuktepe B, et al. Sex-Specific Differences in Patients with Psoriatic Arthritis: A Systematic Review. J Rheumatol 2022;50:jrheum.220386.
[10] Bhole VM, Choi HK, Burns LC, Kellet CV, Lacaille DV, Gladman DD, et al. Differences in Body Mass Index among Individuals with PsA, Psoriasis, RA and the General Population. Rheumatology (Oxford) 2012;51:552-6.
[11] Labitigan M, Bahče-Altuntas A, Kremer JM, Reed G, Greenberg JD, Jordan N, et al. Higher Rates and Clustering of Abnormal Lipids, Obesity, and Diabetes Mellitus in Psoriatic Arthritis Compared with Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2014;66:600-7.
[12] Yagensky V, Schirmer M. Cardiovascular Risks and Risk Stratification in Inflammatory Joint Diseases: A CrossSectional Study. Front Med (Lausanne) 2022;9:786776.
[13] Geng Y, Song ZB, Zhang XH, Deng XR, Wang Y, Zhang ZL. Depression and Anxiety in Patients with Psoriatic Arthritis: Prevalence and Associated Factors. Beijing Da Xue Xue Bao Yi Xue Ban 2020;52:1048-55.
[14] Baraliakos X, Coates LC, Braun J. The Involvement of the Spine in Psoriatic Arthritis. Clin Exp Rheumatol 2015;33:S31-5.
[15] Gottlieb AB, Merola JF. Axial Psoriatic Arthritis: An Update for Dermatologists. J Am Acad Dermatol 2021;84:92-101.
[16] Eder L, Thavaneswaran A, Chandran V, Gladman DD. Gender Difference in Disease Expression, Radiographic Damage and Disability among Patients with Psoriatic Arthritis. Ann Rheum Dis 2013;72:578-82.
[17] Patrizi A, Venturi M, Scorzoni R, Pazzaglia M, Malavolta N, Bardazzi F. Nail Dystrophies, Scalp and Intergluteal/Perianal Psoriatic Lesions: Risk Factors for Psoriatic Arthritis in Mild Skin Psoriasis? G Ital Dermatol Venereol 2014;149:177-84.
[18] Tillett W, Charlton R, Nightingale A, Snowball J, Green A, Smith C, et al. Interval between Onset of Psoriasis and Psoriatic Arthritis Comparing the UK Clinical Practice Research Data link with a Hospital-Based Cohort. Rheumatology (Oxford) 2017;56:2109-113.
[19] Fechtenbaum M, Desoutter J, Delvallez G, Brochot E, Guillaume N, Goëb V. MICA and NKG2D Variants as Risk Factors in Spondyloarthritis: A Case-Control Study. Genes Immun 2019;20:599-605.
[20] Ruiz DG, de Azevedo MN, Lupi O. HLA-B27 Frequency in a Group of Patients with Psoriatic Arthritis. An Bras Dermatol 2012;87:847-50.
[21] Chandran V, Tolusso DC, Cook RJ, Gladman DD. Risk Factors for Axial Inflammatory Arthritis in Patients with Psoriatic Arthritis. J Rheumatol 2010;37:809-15.
[22] Payet J, Goulvestre C, Bialé L, Avouac J, Wipff J, JobDeslandre C, et al. Anticyclic Citrullinated Peptide Antibodies in Rheumatoid and Nonrheumatoid Rheumatic Disorders: Experience with 1162 Patients. J Rheumatol 2014;41:2395-402.
[23] Leung YY, Tam LS, Kun EW, Li EK. Impact of Illness and Variables Associated with Functional Impairment in Chinese Patients with Psoriatic Arthritis. Clin Exp Rheumatol 2008;26:820-6.
[24] FitzGerald O, Haroon M, Giles JT, Winchester R. Concepts of Pathogenesis in Psoriatic Arthritis: Genotype Determines Clinical Phenotype. Arthritis Res Ther 2015;17:115.
[25] Lai TL, Yim CW, Wong PY, Leung MC, Ng WL. Hyperuricemia in Asian Psoriatic Arthritis Patients. Int J Rheum Dis 2018;21:843-9.
[26] AlJohani R, Polachek A, Ye JY, Chandran V, Gladman DD. Characteristic and Outcome of Psoriatic Arthritis Patients with Hyperuricemia. J Rheumatol 2018;45:213-7.
[27] Tsuruta N, Imafuku S, Narisawa Y. Hyperuricemia is an Publisher’s note Whioce Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Independent Risk Factor for Psoriatic Arthritis in Psoriatic Patients. J Dermatol 2017;44:1349-52.
[28] Felten R, Duret PM, Gottenberg JE, Spielmann L, Messer L. At the Crossroads of Gout and Psoriatic Arthritis: “Psout”. Clin Rheumatol 2020;39:1405-13.